06/22/2007 03 FC:1814 PTO/SB/26 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TERMINAL DISCLAIMED TO OBVIATE A DOUBLE DATE: The Paperwork Reduction of the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING **REJECTION OVER A "PRIOR" PATENT**

Docket	Number :	(Optional)	

In re Application of: Unchalee Kositprapa	•
Application No.: 10/634,321	
Filed: August 4, 2003	
For: Pharmaceutical Formulation	
The owner*, Andrx Pharmaceuticals, LLC, of	lication which would extend beyond or patent is defined in 35 U.S.C. 154 er hereby agrees that any patent so r patent are commonly owned. This sessors or assigns. anted on the instant application that or patent, "as the term of said prior
is in any manner terminated prior to the expiration of its full statutory term as presently shortened by a Check either box 1 or 2 below, if appropriate. 1. For submissions on behalf of a business/organization (e.g., corporation, partnership, university, go etc.), the undersigned is empowered to act on behalf of the business/organization.	
I hereby declare that all statements made herein of my own knowledge are true and that all st belief are believed to be true; and further that these statements were made with the knowledge that will made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United Statements may jeopardize the validity of the application or any patent issued thereon.	ful false statements and the like so
2. The undersigned is an attorney or agent of record. Reg. No. 56,878	
MADA	
	June 18, 2007
Signature	Date
HDEMESS1 00000024 10634321 Matthew J. Solow	
130.00 DP Typed or printed name	
·	212-302-8989
rm	Telephone Number
✓ Terminal disclaimer fee under 37 CFR 1.20(d) included.	
WARNING: Information on this form may become public. Credit card information be included on this form. Provide credit card information and authorization on	
*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/SB/96 may be used for making this certification. See MPEP § 324.	
This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the	public which is to file (and by the USPTO

This collection of information is required by 37 CPR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.